Tag Cloud

What is a tag cloud?

Current tags: Clear current tags
View full tag cloud
Advertisement
Q

Is there an increased risk of breast cancer in women using vaginal oestrogen creams?

Associated tags: breast cancer, Cancer, etiology, topical oestrogen, Women's health

Question DetailsView Comments (0)
A

ANSWER

provided by Trip / NLH
Search
Moderate
Appraisal
Moderate
Confidence
Poor

Answer Rating key

search strong
appraisal weak
confidence moderate

Question answered:03/04/08

It would appear that there is not enough evidence to answer this question.

 

A consensus statement published by the American National Institutes of Health in 2005 states [1]:

 

“Vaginal estrogen preparations to treat vaginal dryness and pain with intercourse may also be an attractive option for these women. Such topical therapies are known to increase circulating estrogen levels, but by much smaller amounts than oral estrogen therapy. Because these topical therapies have not been studied in large numbers of women for long periods of time, actual levels of risk for long-term complications, such as breast cancer occurrence or recurrence, while probably much lower than those of oral therapy, are not fully known.”

 

The CKS guideline on menopause [2] reports:

 

“Vaginal oestrogens:
Low-dose oestrogen therapy is preferred because it incurs no adverse endometrial effects and a progestogen is not required for endometrial protection [Rees and Purdie, 2006a]. Vaginal oestrogen therapy may be required long-term, as symptoms recur when treatment is stopped. However the endometrial safety of long term or repeated use of topical vaginal oestrogens is uncertain [CSM, 2003b].”

 

The CSM advice mentioned above, although focussed on endometrial cancer, suggests [3] using the lowest effective amount (to avoid systemic absorption) and to interrupt treatment at least annually to re-assess the need for treatment.

 

References

1) http://consensus.nih.gov/2005/2005MenopausalSymptomsSOS025PDF.pdf
2) http://cks.library.nhs.uk/menopause/view_whole_topic_review
3) http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON007450&RevisionSelectionMethod=LatestReleased


DISCLAIMER: TRIPanswers is a collection of clinical questions and answers.  Each provider will have their own methodology in answering questions and these are likely not to be as rigorous as systematic review.  If you have any doubt as to the implications of this contact the Q&A Service Provider for further information. This document is presented for information purposes only. This document cannot and should not be used as a basis of diagnosis or choice of treatment, and is in no way intended to replace professional medical care or attention by a qualified practitioner. TRIPanswers and TRIP Database Ltd are not responsible or liable for, directly or indirectly, ANY form of damage whatsoever resulting from the use/misuse of information contained in or implied by this document.  Also, ensure you have read the terms and conditions for using the site.

Need to search for more evidence?

Help us improve this answer

Leave comments or suggestions below

Disclaimer:

TRIP will review each comment and will only publish those we feel will enhance a particular answer.  As a result of the review process there will be a delay between submission and publication of accepted comments.